Women's Health

Investigators used SC144, an FDA-approved molecule, to find a new pathway for a generation of nonhormonal contraceptives.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some social and cultural aspects that may contribute to hypoactive sexual desire disorder going untreated in women.

Experts discuss women's health and health care during the COVID-19 pandemic as part of the Pharmacy Times® Pharmacy Focus webcast series.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some of the common practices for the treatment of hypoactive sexual desire disorder in women and men.

Those with the disorder during gestation and who were examined 2 to 7-years after delivery had a more than 3-fold increased risk for incident high blood pressure, results of the analysis show.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses whether hypoactive sexual desire disorder is associated with psychological and/or emotional components.

Oral ibrexafungerp, a fungicidal oral treatment to prevent recurrent vaginal yeast infections, achieved superiority over the placebo for the primary and key secondary study endpoints.

One out of every 4 pharmacists in Georgia said emergency contraception was not available at the store and ended the call.

New study results show that rapidly adding pounds in the first and final months of gestation likely plays a key role in the development of excess fat tissue in female children and adolescents.

Selinexor demonstrated a 37% increase in probability that patients treated with the drug will be in remission at 12 months.

Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.

In the third episode of Coffee With Suzy, Suzanne Soliman, PharmD, BCMAS, spoke with Seena Haines, PharmD, BCACP, to share insights on improving self-care for women in pharmacy.

Remifemin provides an alternative to hormone replacement therapy for the treatment of menopausal symptoms.

OptiBalance is a probiotic that helps at the start of menstruation to maintain a healthy balance.

Estroven can help reduce menopause symptoms such as hot flashes and night sweats, and helps to manage daily stress.

Suzanne Soliman, PharmD, BCMAS, discussed alcohol abuse and when the pharmacist becomes the patient with Sherry Price, PharmD, MBA, APh, BCPS, pharmacist and creator of the Drink Less Lifestyle podcast and program.

Cystex provides prophylaxis for urinary tract infections.

The findings suggest that pregnant women should not delay COVID-19 vaccination until late pregnancy.

These results suggest that maternal diet during pregnancy can significantly affect obesity risk in children.

Pamprin Multi-Symptom is a combination medicine used to treat the symptoms of premenstrual syndrome.

In the first episode of Coffee With Suzy, Suzanne Soliman, PharmD, BCMAS, spoke with the main moderators of the Pharmacist Moms Group about the importance of women in pharmacy.

New trial results showed statistically significant improvements in overall survival and progression-free survival.

Becoming involved in different charitable causes and leadership programs can only benefit pharmacists.

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Approximately 400,000 women undergo breast implant surgeries each year in the United States, and selecting an implant is an important and personal part of the process.

Midol treats painful menstruation, typically involving abdominal cramps.

New study results suggest that severe depression and sexual dysfunction, in particular, can affect a woman's attention, language, orientation, recall, registration, and visuospatial skills.

These mothers are approximately 17% less likely to die from cardiovascular disease, 14% less likely to develop coronary heart disease, and 12% less likely to suffer a stroke, the data show.

The data were used to evaluate effect of the ACA state Medicaid on insurance coverage, health care use, and health outcomes measured between 1 month prior to conception through 1 year postpartum, and neonatal outcomes within 27 days of birth.